Based on these data currently a Phase Ib study, where the combination of pan PI3K inhibitor with weekly cisplatin and radiotherapy is tested, is ongoing in locally advanced HNSCC patients (NCT02113878). This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.